# Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases

> **NCT01444807** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 132 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT01444807
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-12
- **Primary completion:** 2017-03
- **Final completion:** 2022-03
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2021-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01444807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01444807, "Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01444807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*